Taken together, the mortality studies indicate that there is clearly increased mortality with parkinsonism; that levodopa may reduce mortality, particularly in the earlier stages of the disease, but fails to eliminate the excess mortality of patients with parkinsonism; and the effects of levodopa treatment on mortality are less apparent later in the disease.